| Balance Sheets | 2025-07-31 | |||
|---|---|---|---|---|
| Receivables | 0 | |||
| Cash and cash equivalents | 1,495 | |||
| Short-term investments | 14,534 | |||
| Prepaid expenses and other current assets | 1,420 | |||
| Total current assets | 17,449 | |||
| Operating lease right-of-use asset | 202 | |||
| Total assets | 17,651 | |||
| Accounts payable | 276 | |||
| Accrued expenses | 1,751 | |||
| Operating lease liability, current | 39 | |||
| Total current liabilities | 2,066 | |||
| Operating lease liability, non-current | 174 | |||
| Total liabilities | 2,240 | |||
| Preferred stock, value | 0 | |||
| Preferred stock, value-Series AConvertible Preferred Stock | 0 | |||
| Treasury stock, 2,000 shares at cost as of october 31, 2024 | 0 | |||
| Common stock, par value .01 per share 100,000,000 shares authorized 32,822,109 and 32,196,862 shares issued and outstanding as of july 31, 2025 and october 31, 2024, respectively | 328 | |||
| Additional paid-in capital | 265,249 | |||
| Accumulated deficit | -248,982 | |||
| Total shareholders equity | 16,595 | |||
| Noncontrolling interest (note 2) | -1,184 | |||
| Total equity | 15,411 | |||
| Total liabilities and equity | 17,651 | |||
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)